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AGS: aminoglycosides 
            VTC: Vestibular Testing Center  
            DVA: Dynamic visual acuity  
            VNG: Testing to determine the presence of oscillopsia, videonystagmography  
            SCEV: Peak slow component eye velocity (SCEV) 
            VOR: Vestibulo-ocular reflex  
            DPOAE: Distortion Product Otoacoustic Emissions   
            vHIT: the video head impulse test 
            VEMP: vestibular evoked myogenic potential            
Summary/ Abstract 
Aim: Cystic Fibrosis (CF) patients frequently use aminoglycosides (AGS) to treat CF 
exacerbation due to colonization with Pseudomonas aeruginosa.  Although AGS can cause 
vestibular and auditory sensory losses that can negatively impact quality of life, little is known 
about the prevalence of vestibular loss in this population. The aim of this study was to determine 
the prevalence of hearing loss and/or vestibular dysfunction in CF patients treated with AGS. 
Methods: The relationship between hearing status and vestibular status was also investigated. 
Hearing was determined to be normal or abnormal based on pure tone air and bone conduction 
thresholds. Vestibular outcome was divided into four categories; normal, non-lateralized 
vestibular dysfunction, unilateral loss, and bilateral loss based on results of post head shaking 
testing, positional and positioning testing, bithermal calorics, sinusoidal and rotational step 
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testing. Results: Of our cohort of 71 patients, 56 (79%) patients have vestibular system 
dysfunction while only 15 (21%) have normal vestibular system function. Overall, 16 patients 
(23%) have hearing loss.  In considering the relationship between auditory and vestibular 
function, 12 (17%) demonstrated both normal hearing and normal vestibular function and 13 
(18%) have both hearing loss and abnormal vestibular function. Of the 55 (78%) patients with 
normal hearing, 43 (61%) have vestibular dysfunction, while 3 (4%) of patients with normal 
vestibular function have hearing loss. Conclusion: These results suggest that monitoring hearing 
alone is insufficient to detect ototoxicity in CF patients being treated with systemic AGS.  
 
Introduction 
Cystic Fibrosis (CF) is the most common life threatening, autosomal recessive disorder in 
the Caucasian population 1. Patients with CF constitute a group that use aminoglycosides (AGS) 
at a high rate due to the chronic colonization by Pseudomonas aeruginosa (P. aeruginosa) and 
frequent pulmonary exacerbation 2-5.  Aminoglycoside antibiotics can cause vestibular and 
auditory sensory losses that can seriously impact a patient’s quality of life 6-7. Loss of auditory 
function has been well documented by otoacoustic emission testing and clinical audiometry 8-14. 
However, the prevalence of vestibular dysfunction/toxicity among patients exposed to AGS has 
not been reported. We could find only two systematic studies of vestibular disorders in CF 
patients. Both studies used caloric irrigation asymmetry to assess function and both were 
restricted to CF patients who received tobramycin. Thomsen et al.15 evaluated 53 pediatric 
patients, only one of which had a caloric asymmetry. Scheenstra et al.16 evaluated 23 adult CF 
patients who received systemic tobramycin and reported the prevalence of vestibular disorders as 
30.4% of their population. Complicating factors in identifying the prevalence of vestibular 
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dysfunction are the variable presentation of symptoms within individual patients, the variable 
compensatory adjustments of the symptoms, and the difficulty in measuring vestibular function 
in pediatric patients. Furthermore, there are no commonly accepted protocols for monitoring 
vestibular function, especially in children 17-20. In addition, CF patients typically receive multiple 
AGS treatments that may include gentamicin and amikacin as well as tobramycin (systemically 
and inhaled). These factors lead to difficulty is estimating the prevalence of vestibular 
dysfunction in this patient population 21-24. 
There is an urgent need to assess the prevalence of ototoxicity in CF patients. First, as 
noted on the Cystic Fibrosis Foundation Patient Registry, more than 75 percent of people with 
CF are diagnosed by age 2 and there is a steady increase in the median survival age of CF 
patients to over 40 years of age; more than half of these patients are older than 18 years of age 25-
30. Second, multiple exposures to AGS in CF patients can lead to cumulative damage to the 
auditory and vestibular systems over the lifetime of the patients, the symptoms of which are 
largely irreversible and disabling.  
Symptoms of vestibular dysfunction may include oscillopsia (disturbed vision with head 
motion), dizziness, motion sickness, and unsteadiness when standing or walking, especially in 
the dark 31-36. These symptoms negatively impact patients’ quality of life and can lead to 
significant disability including an increased rate of falling. Despite the serious impact of 
ototoxicity and vestibular dysfunction on quality of life, the two studies cited above are the only 
systematic studies of vestibular ototoxicity in patients 15-16. In fact, much of the literature on 
aminoglycoside ototoxicity is devoted to kidney disease and/or auditory dysfunction 37-38.  For 
this reason, we conducted a study to establish the prevalence of vestibular system involvement in 
patients treated with systemic AGS for treatment of CF pulmonary exacerbation. Hearing was 
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also evaluated to determine the relationship between auditory and vestibular loss in individual 
patients. 
 
Methods 
Patient Selection: 
 CF Patients, 8 years of age and older who attended the University of Michigan CF Center 
and received intravenous AGS for treatment of pulmonary exacerbation or pneumonia, were 
eligible to participate in this study. Patients less than 8 years were excluded from the study 
because of concerns that they would not be able to fully cooperate with the testing as well as 
concerns about appropriate diagnostic criteria in young children 39, 19. Testing was conducted as 
close to the start of a treatment course as possible although we did not control for the number of 
prior exposures to AGS. As a result, some patients had multiple courses of AGS prior to testing. 
While most of the patients’ exposures to intravenous AGS were limited to tobramycin and/or 
gentamicin, some patients were treated with intravenous amikacin. Finally, because this patient 
population is frequently treated with multiple antibiotics over time, both inhaled and intravenous, 
the aminoglycoside exposure was variable within and across patients.  
 Auditory and vestibular testing was completed in the Vestibular Testing Center (VTC) at 
the University of Michigan Health System. Prior to audiologic or vestibular testing, otoscopic 
inspection was performed in order to determine that the patients’ ear canals were free of cerumen 
or other debris that would obstruct visualization of the tympanic membrane and might affect the 
auditory thresholds or interfere with caloric irrigation during vestibular testing.  
Audiologic Assessment: 
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Audiologic testing for subjects in this study was performed at the time of enrollment or at the 
time of vestibular testing. Testing consisted of pure tone air conduction behavioral thresholds at 
octave frequencies from 250-8,000 Hz. When evidence of hearing loss was present, bone 
conduction testing was conducted at octave frequencies from 250-4000 Hz. Acoustic immittance 
testing (tympanometry and acoustic reflexes) was completed to rule out the presence of middle 
ear pathology.  
Vestibular Assessment: 
A case history was obtained to ascertain whether the subjects had prior symptoms related 
to vestibular dysfunction or other co-morbidities that might impact vestibular function. The 
vestibular evaluation included completion of dynamic visual acuity (DVA) testing to determine 
the presence of oscillopsia, videonystagmography (VNG), and sinusoidal and rotational step 
testing. The procedures for each portion of the battery are summarized in the following 
paragraphs. 
DVA was assessed by asking subjects to read from a Snellen eye chart positioned at a 
distance of 10 ft. Visual acuity was determined while the patient’s head was still and with head 
rotation back and forth at 1-2 Hz. A change in visual acuity with head rotation of more than two 
lines was considered to be abnormal and suggestive of oscillopsia. 
VNG testing included recording horizontal and vertical eye movements for each eye 
using infrared cameras and digital video technology. All of the video data were digitally stored 
for analysis. Since eye movements form the basis of our vestibular assessment, tests of visual 
fixation, smooth pursuit, and random saccades were performed to rule out oculomotor disorders. 
The remaining tests were completed with vision denied to prevent visual suppression of the 
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vestibular response. Following oculomotor testing, eye movements were recorded with the 
patient’s head and body in various positions as well as following rapid head shaking. Eye 
movements were evaluated for the presence of nystagmus in any condition. Alternate bithermal 
caloric irrigations using warm and cool water (open loop system) were performed to evaluate the 
response of the horizontal semicircular canal of each ear independently. Eye movements were 
recorded post irrigation and examined for the presence of nystagmus. Peak slow component eye 
velocity (SCEV) during nystagmus is the relevant dependent variable that is computed from the 
video data. The total SCEV for each ear was compared to determine whether a significant 
asymmetry in the vestibulo-ocular reflex (VOR) was present based on the clinical criteria used in 
the VTC. Specifically, a significant asymmetry was defined as a unilateral weakness > 25%. 
Sinusoidal rotary chair testing was conducted over a range of frequencies from 0.01 to 
1.28 Hz. Unlike caloric tests, which employ non-physiological stimuli, the rotary chair test 
employs a natural stimulus to excite the vestibular system bilaterally. For each stimulus 
frequency, the phase, gain, and asymmetry of the patient’s eye movements were calculated. Gain 
is defined as the ratio of the eye movements (SCEV) compared to the speed of the chair 
movement, phase is a measure of the timing relationship between the eyes and the chair, and 
asymmetry is the relative gain for clockwise and counter clockwise rotations. 
Patients with bilateral vestibular loss usually present with decreased gain values, 
especially at the lowest test frequencies. For frequencies at which there are adequate gain 
responses to determine phase and symmetry values (> 0.2), increased phase leads may also be 
present. With unilateral vestibular loss, increased phase leads (with or without asymmetries) are 
often present. 
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Rotational step testing was also performed during which each patient was abruptly 
accelerated to a high angular velocity (100 deg/sec or 240 deg/sec), which typically resulted in a 
brisk nystagmus. Rotation continued at a constant speed long enough for the nystagmus to 
subside. After a period of constant velocity rotation, the patient was abruptly decelerated to a 
stop, which was experienced as acceleration in the opposite direction and was accompanied by 
another burst of brisk nystagmus that decayed over time. Step testing included both clockwise 
and counterclockwise acceleration and the deceleration from each. The dependent variables of 
interest are the peak SCEV for each of the four steps as well as the decay time, which is referred 
to as the VOR time constant. Bilateral vestibular loss results in gain reductions and short time 
constants. Short time constants may also be present in unilateral and non-lateralizing vestibular 
loss. 
For each portion of the test battery individual subject’s data were determined to be 
normal or abnormal based on the clinical criteria that are used for all patients who are evaluated 
in the VTC. These criteria are derived from norms that were established by equipment 
manufacturers and our own clinical data. Typically, a result is considered clinically significant if 
it exceeds two standard deviations from the mean values for normal subjects.  
The study was approved by The University of Michigan Institutional Review Board 
(IRB).  
 
Results 
 Vestibular test results for each patient were described as falling into one of four 
categories. Specifically, they were considered to be normal if the findings on each of the portions 
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of the test battery fell within the normal range based upon our clinical criteria. When that was not 
the case, they fell into one of three abnormal categories as seen in Table 1. Category A includes 
non-lateralizing evidence of peripheral vestibular system involvement, such as the presence of 
spontaneous, post head shaking, or positional nystagmus, increased phase leads and/or 
asymmetries in sinusoidal rotational testing, or evidence of a short time constant in rotational 
step testing. To be included in this category, a patient’s data demonstrated one or more abnormal 
findings as mentioned above. Category B represents evidence of a unilateral peripheral vestibular 
loss based upon a significant asymmetry in caloric results. Findings that are included in Category 
A may also be present. Category C represents evidence of a bilateral peripheral vestibular loss 
including bilateral reductions in caloric findings and/or gain reductions in rotational testing at 
one or more frequencies. One or more findings that are included in Category A, as well as 
evidence of an asymmetry, may also be present.  
The hearing status of individual patients was separated into two categories: normal or 
hearing loss. Patients were considered to have ormal hearing when behavioral thresholds at all 
standard audiometric frequencies fell within the normal range (i.e. < 25 dB HL) for air 
conduction and bone conduction. Although Distortion Product Otoacoustic Emissions (DPOAE) 
were recorded for some patients, the data presented for this cohort is limited to tests that were 
completed for every participant. High frequency pure tone thresholds were not obtained due to 
equipment limitations.   
 The patients’ vestibular data to date are summarized in Figure 1. We have completed 
vestibular testing on 71 patients, ranging in age from 8-56 years (mean = 18.3 years, median = 
17 years). The sample included 29 (41%) males and 42 (59%) females. Of the 71 patients, 27 
(38%) have evidence of non-lateralized peripheral vestibular system involvement, 8 (11%) have 
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significant unilateral vestibular losses, and 21 (30%) have evidence of bilateral vestibular system 
paresis. Of the sample population, 56 (79%) individuals demonstrated the presence of vestibular 
system dysfunction while only 15 individuals (21%) have no evidence of vestibular system 
involvement based upon the results of testing. In terms of hearing status, 16 patients (23%) have 
evidence of hearing loss. Of note, the prevalence of vestibular loss in this patient population is 
much greater than is the prevalence of hearing loss. Additionally, a cursory review of patients’ 
AGS exposures revealed no apparent relationship between specific antibiotic exposure at the 
time of testing and hearing loss or vestibular loss. For example, normal hearing and hearing loss 
occurred for all three AGS as did normal vestibular function and vestibular loss. Although not a 
primary objective of this study, our data do not provide evidence that specific medications are 
primarily cochleotoxic or vestibulotoxic. 
 We were also interested in examining the relationship between vestibular loss and 
hearing status, the results of which is displayed in Table 2. Of the patient population evaluated, 
only 12 (17%) demonstrated both normal heari g and normal vestibular function and 13 (18%) 
showed evidence of both hearing loss and abnormal vestibular function. Of the 55 (78%) patients 
with normal hearing, 43 (61%) have vestibular dysfunction based upon the results of testing, and 
3 (4%) of patients with normal vestibular function have hearing loss. Based on these data, there 
is no clear relationship between hearing status and vestibular function in this group. 
Discussion 
These data demonstrate that our overall prevalence rate of vestibular dysfunction of 79% 
(38% with non-lateralizing peripheral involvement and 41% with either a significant unilateral or 
bilateral paresis) in our cohort of CF patients who were exposed to systemic aminoglycosides is 
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much higher than previously recognized 32. Scheenstra et al. included subjects exposed to one or 
more courses of systemic tobramycin and who had not received any other ototoxic 
aminoglycoside. In contrast, some of the patients included in our study were exposed to multiple 
AGS including gentamicin, tobramycin, and/or amikacin. Because of incomplete medical 
records, we were unable to accurately determine the cumulative dosages of aminoglycoside 
antibiotics received by our patients. Nevertheless, the prevalence of vestibular ototoxicity in our 
sample of CF patients is an important finding that argues for more systematic testing of 
vestibular function in this patient population. Despite the awareness and attention given to the 
risk of hearing loss in patients treated with AGS, our data demonstrate that there is an even 
greater risk of vestibular dysfunction and its attendant disabling symptoms. 
Vestibular testing of CF patients is infrequently performed at most CF centers. The most 
likely explanations for lack of testing are insufficient knowledge of the symptoms and 
prevalence of vestibular disorders and the complexity of the tests themselves. For example, 
although “dizziness” is often cited as a vestibular symptom, it is not as common as oscillopsia or 
decreased visual acuity among patients with bilateral vestibular dysfunction. Additionally, 
patients may underreport symptoms. For example, among our patients, although most denied 
symptoms of oscillopsia when questioned, all of the patients with bilateral vestibular loss 
demonstrated impaired dynamic visual acuity when tested. Furthermore, patients may 
compensate for vestibular losses and be asymptomatic after an ototoxic insult; however, cell 
losses in the peripheral labyrinth caused by ototoxicity are cumulative (sensory cells do not 
regenerate) 7,17,20,31,39. Subsequent ototoxic insults will eventually exhaust the brain’s 
compensatory capacity.   
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The complexity of vestibular testing and discomfort to the patient are also barriers to 
systematic evaluation. Only a small number of our young pediatric patients were willing to 
submit to a complete vestibular test battery and an even smaller number were willing to be 
retested after subsequent exposures to AGS. These patients were particularly reluctant to receive 
caloric and rotary chair tests, which represent the gold standards for vestibular evaluation. The 
development of new vestibular tests such as the video head impulse test (vHIT) and vestibular 
evoked myogenic potential (VEMP) tests may be better tolerated by CF patients as can be 
performed in less time with less physical or psychological discomfort. Additionally, creation of 
facilities and protocols that are adapted for children may be helpful. However, systematic studies 
to determine the sensitivity and specificity of these tests relative to rotary chair and caloric tests 
in adult and pediatric patient populations are still needed. 
Our data also demonstrate that the prevalence of hearing loss in our cohort of patients 
was relatively low at 22%. In addition, there is no discernable relationship between hearing 
status and vestibular function in CF patients exposed to aminoglycoside therapies. Specifically, 
61% of patients with vestibular loss have normal hearing and 4% of patients with normal 
vestibular function have hearing loss. Furthermore, there are patients with normal hearing 
represented in all three categories of vestibular disorders. An important limitation of our study 
related to its sensitivity in identifying hearing loss is that data are limited to standard frequencies. 
In a recent investigation, Al-Malky and colleagues40 reported a similar prevalence rate of 21% 
using standard audiometry whereas the prevalence increased to 24% using extended high 
frequency (EHF) audiometry.  Additionally, DPOAE results were significantly correlated with 
EHF results in their cohort. Importantly, these results suggest that monitoring auditory function 
alone in this population of patients is an insufficient way to look for evidence of ototoxicity in 
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individual patients with CF being treated with systemic AGS. While it is apparent that high 
frequency audiometry and DPOAE testing may be more sensitive measures of auditory sensory 
loss in this patient population, the prevalence of vestibular loss in our patient population is much 
greater than hearing loss. Furthermore, because of the substantial negative impact of vestibular 
loss on function and quality of life, early identification is critical. 
 Providing patients and families with information about the role of the vestibular system 
is important, particular related to maintenance of clear vision with head movements and in 
postural control and balance. When treatment with systemic AGS is necessary, having an 
understanding of the potential effects of ototoxicity and its associated symptoms will enable 
patients to identify early changes in order to alert their health care team. In addition, early 
identification of vestibular loss provides an opportunity to counsel patients and families about 
important safety issues. Patients in our cohort were counseled about the test results and their 
implications by the audiologist who performed testing. Based on the results of this investigation, 
obtaining baseline measures of auditory and vestibular function as well as monitoring function in 
conjunction with each aminoglycoside exposures are warranted. Early diagnosis of sensory loss 
may enable health care providers to alter treatment in some cases. When that is not possible, 
knowing about vestibular loss can facilitate timely referral to vestibular physical therapy when 
rehabilitation is indicated to improve gaze stabilization, promote sensory substitution in the case 
of bilateral vestibular loss, and facilitate habituation of symptoms. Our patients were offered 
appointments for physical therapy when appropriate. 
As has been discussed, we did not control for the number or type of aminoglycoside 
exposure for this study. We also did not investigate whether serial changes in function with 
repeated exposure are detectable. As a result, additional studies that attempt to look at vestibular 
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function relative to the type and dosage of aminoglycosides administered (both inhaled and 
intravenous) and the cumulative impact of repeated exposures are indicated to further define 
these relationships. 
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Figure 1. Prevalence of vestibular and auditory dysfunction in CF patients who received one or more 
intravenous courses of aminoglycoside antibiotics.  
     Table 1. Criteria for each category of vestibular disorders. 
 
Nonlateralized Peripheral 
Vestibular Disorder (Category 
A) 
Unilateral Vestibular Paresis 
(Category B) 
Bilateral Vestibular Paresis 
(Category C) 
Spontaneous nystagmus 
 
Significant post head shaking 
nystagmus 
 
Significant positional 
nystagmus 
 
Short time constants for 
rotational steps 
 
Increased phase leads at any 
sinusoidal frequency 
 
Significant chair asymmetries 
Caloric inter-ear asymmetry 
greater than or equal to 25% 
 
One or more of the results 
listed in Category A may also 
be present 
Each of the four caloric 
responses less than 10 deg/sec 
 
Gain reductions in rotational 
step testing 
 
Gain reductions in sinusoidal 
rotational testing 
 
One or more of the results 
listed in Category A may also 
be present 
 
      
 
 Table 2. Co-morbidity of vestibular and auditory losses in CF patients.  
 
 Normal Auditory Abnormal Auditory 
Normal Vestibular 12 3 
Abnormal Vestibular 43 13 
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